DK3777840T3 - Rna-formulering til immunterapi - Google Patents
Rna-formulering til immunterapi Download PDFInfo
- Publication number
- DK3777840T3 DK3777840T3 DK20189077.9T DK20189077T DK3777840T3 DK 3777840 T3 DK3777840 T3 DK 3777840T3 DK 20189077 T DK20189077 T DK 20189077T DK 3777840 T3 DK3777840 T3 DK 3777840T3
- Authority
- DK
- Denmark
- Prior art keywords
- immunotherapy
- rna formulation
- rna
- formulation
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
- A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
- A61K48/0033—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being non-polymeric
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
- A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
- A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Dispersion Chemistry (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EP2012/001319 WO2013143555A1 (en) | 2012-03-26 | 2012-03-26 | Rna formulation for immunotherapy |
| EP18171522.8A EP3427723B1 (en) | 2012-03-26 | 2013-03-25 | Rna formulation for immunotherapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3777840T3 true DK3777840T3 (da) | 2025-06-02 |
Family
ID=48044720
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK13713356.7T DK2830593T3 (da) | 2012-03-26 | 2013-03-25 | Rna-formulering til immunterapi |
| DK20189077.9T DK3777840T3 (da) | 2012-03-26 | 2013-03-25 | Rna-formulering til immunterapi |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK13713356.7T DK2830593T3 (da) | 2012-03-26 | 2013-03-25 | Rna-formulering til immunterapi |
Country Status (20)
| Country | Link |
|---|---|
| US (3) | US10485884B2 (da) |
| JP (4) | JP6279545B2 (da) |
| CN (2) | CN104302276A (da) |
| AU (3) | AU2013242512B2 (da) |
| BR (1) | BR112014022562A8 (da) |
| CA (2) | CA3088428C (da) |
| DK (2) | DK2830593T3 (da) |
| ES (3) | ES2719480T3 (da) |
| HR (1) | HRP20201578T1 (da) |
| HU (2) | HUE044594T2 (da) |
| LT (2) | LT2830593T (da) |
| MX (3) | MX377244B (da) |
| NZ (1) | NZ628328A (da) |
| PL (1) | PL3777840T3 (da) |
| PT (2) | PT2830593T (da) |
| RS (1) | RS61002B1 (da) |
| SI (1) | SI3427723T1 (da) |
| SM (1) | SMT202000603T1 (da) |
| TR (1) | TR201904758T4 (da) |
| WO (2) | WO2013143555A1 (da) |
Families Citing this family (230)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9408909B2 (en) * | 2007-09-14 | 2016-08-09 | Vrije Universiteit Brussel | Enhancing the T-cell stimulatory capacity of human antigen presenting cells in vitro and in vivo and its use in vaccination |
| CA2807552A1 (en) | 2010-08-06 | 2012-02-09 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| ES3005233T3 (en) | 2010-10-01 | 2025-03-14 | Modernatx Inc | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof |
| JP2014511687A (ja) | 2011-03-31 | 2014-05-19 | モデルナ セラピューティクス インコーポレイテッド | 工学操作された核酸の送達および製剤 |
| DK3336082T3 (da) | 2011-06-08 | 2020-04-27 | Translate Bio Inc | Spaltelige lipider |
| US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| EP2763701B1 (en) | 2011-10-03 | 2018-12-19 | Moderna Therapeutics, Inc. | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof |
| ES3065854T3 (en) | 2011-12-07 | 2026-05-08 | Alnylam Pharmaceuticals Inc | Biodegradable lipids for the delivery of active agents |
| JP2015501844A (ja) | 2011-12-16 | 2015-01-19 | モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． | 修飾ヌクレオシド、ヌクレオチドおよび核酸組成物 |
| WO2013143555A1 (en) | 2012-03-26 | 2013-10-03 | Biontech Ag | Rna formulation for immunotherapy |
| US9254311B2 (en) | 2012-04-02 | 2016-02-09 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of proteins |
| US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
| WO2013151663A1 (en) | 2012-04-02 | 2013-10-10 | modeRNA Therapeutics | Modified polynucleotides for the production of membrane proteins |
| US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
| ES2921623T3 (es) | 2012-11-26 | 2022-08-30 | Modernatx Inc | ARN modificado terminalmente |
| BR122021025267B1 (pt) | 2013-02-22 | 2023-12-05 | Curevac Ag | Partes de kit e composição farmacêutica compreendendo um inibidor da via de pd-1 |
| WO2014127917A1 (en) | 2013-02-22 | 2014-08-28 | Curevac Gmbh | Combination of vaccination and inhibition of the pd-1 pathway |
| US10258698B2 (en) | 2013-03-14 | 2019-04-16 | Modernatx, Inc. | Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions |
| US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
| WO2015048744A2 (en) | 2013-09-30 | 2015-04-02 | Moderna Therapeutics, Inc. | Polynucleotides encoding immune modulating polypeptides |
| KR20160067219A (ko) | 2013-10-03 | 2016-06-13 | 모더나 세라퓨틱스, 인코포레이티드 | 저밀도 지단백질 수용체를 암호화하는 폴리뉴클레오타이드 |
| JP6822841B2 (ja) | 2014-03-09 | 2021-01-27 | ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア | オルニチントランスカルバミラーゼ（ｏｔｃ）欠損症の処置において有用な組成物 |
| ES2754239T3 (es) | 2014-03-12 | 2020-04-16 | Curevac Ag | Combinación de vacunación y agonistas de OX40 |
| DK3134131T3 (en) * | 2014-04-23 | 2022-02-07 | Modernatx Inc | Nucleic acid vaccines |
| IL316479A (en) | 2014-06-25 | 2024-12-01 | Acuitas Therapeutics Inc | Novel lipids and lipid nanoparticle compositions for nucleic acid delivery |
| JP6929791B2 (ja) | 2015-02-09 | 2021-09-01 | デューク ユニバーシティ | エピゲノム編集のための組成物および方法 |
| US10780021B2 (en) | 2015-02-26 | 2020-09-22 | Sio2 Medical Products, Inc. | Cycloolefin polymer container with a scratch resistant and anti-static coating |
| WO2016155809A1 (en) | 2015-03-31 | 2016-10-06 | Biontech Rna Pharmaceuticals Gmbh | Lipid particle formulations for delivery of rna and water-soluble therapeutically effective compounds to a target cell |
| EP3173092B1 (en) | 2015-04-22 | 2019-06-26 | CureVac AG | Rna containing composition for treatment of tumor diseases |
| JP6851319B2 (ja) | 2015-04-27 | 2021-03-31 | ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア | ヒト疾患のＣＲＩＳＰＲ／Ｃａｓ９媒介性の修正のためのデュアルＡＡＶベクター系 |
| JP2018526321A (ja) | 2015-04-27 | 2018-09-13 | ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア | 適応免疫応答を誘導するためのヌクレオシド修飾ｒｎａ |
| WO2016180467A1 (en) | 2015-05-11 | 2016-11-17 | Biontech Cell & Gene Therapies Gmbh | Enhancing the effect of car-engineered t cells by means of nucleic acid vaccination |
| US11090332B2 (en) * | 2015-05-21 | 2021-08-17 | Regen BioPharma, Inc. | Antigen specific mRNA cellular cancer vaccines |
| HUE067372T2 (hu) | 2015-06-29 | 2024-10-28 | Acuitas Therapeutics Inc | Lipidek és nanoszemcsés lipid formulázások nukleinsavak beadására |
| WO2017015457A1 (en) * | 2015-07-21 | 2017-01-26 | Modernatx, Inc. | Ebola vaccine |
| WO2017015637A1 (en) | 2015-07-22 | 2017-01-26 | Duke University | High-throughput screening of regulatory element function with epigenome editing technologies |
| WO2017020026A1 (en) | 2015-07-30 | 2017-02-02 | Modernatx, Inc. | Concatemeric peptide epitopes rnas |
| WO2017035416A2 (en) | 2015-08-25 | 2017-03-02 | Duke University | Compositions and methods of improving specificity in genomic engineering using rna-guided endonucleases |
| RS63030B1 (sr) | 2015-09-17 | 2022-04-29 | Modernatx Inc | Jedinjenja i kompozicije za intracelularno isporučivanje terapeutskih sredstava |
| EP4089175A1 (en) | 2015-10-13 | 2022-11-16 | Duke University | Genome engineering with type i crispr systems in eukaryotic cells |
| CN108430456B (zh) | 2015-10-22 | 2022-01-18 | 摩登纳特斯有限公司 | 癌症疫苗 |
| AU2016342048B2 (en) * | 2015-10-22 | 2022-09-08 | Modernatx, Inc. | Broad spectrum influenza virus vaccine |
| EP3365009A4 (en) * | 2015-10-22 | 2019-07-03 | ModernaTX, Inc. | VACCINES AGAINST HERPES SIMPLEX VIRUS |
| RS63986B1 (sr) | 2015-10-28 | 2023-03-31 | Acuitas Therapeutics Inc | Novi lipidi i lipidne formulacije nanočestica za isporuku nukleinskih kiselina |
| US20190169262A1 (en) * | 2015-12-04 | 2019-06-06 | Board Of Regents, The University Of Texas System | Slc45a2 peptides for immunotherapy |
| CA3007955A1 (en) | 2015-12-10 | 2017-06-15 | Modernatx, Inc. | Lipid nanoparticles for delivery of therapeutic agents |
| JP7114465B2 (ja) | 2015-12-22 | 2022-08-08 | モデルナティエックス インコーポレイテッド | 薬剤の細胞内送達のための化合物および組成物 |
| EP3405579A1 (en) | 2016-01-22 | 2018-11-28 | Modernatx, Inc. | Messenger ribonucleic acids for the production of intracellular binding polypeptides and methods of use thereof |
| WO2017162265A1 (en) | 2016-03-21 | 2017-09-28 | Biontech Rna Pharmaceuticals Gmbh | Trans-replicating rna |
| WO2017162266A1 (en) | 2016-03-21 | 2017-09-28 | Biontech Rna Pharmaceuticals Gmbh | Rna replicon for versatile and efficient gene expression |
| EP3443081A4 (en) | 2016-04-13 | 2019-10-30 | Duke University | CRISPR / CAS9-BASED REPRESSORS FOR IN VIVO SHUT-OFF OF GEN-TARGETS AND METHOD OF USE |
| US20190167811A1 (en) | 2016-04-13 | 2019-06-06 | Modernatx, Inc. | Lipid compositions and their uses for intratumoral polynucleotide delivery |
| CA3021645A1 (en) | 2016-04-29 | 2017-11-02 | Icahn School Of Medicine At Mount Sinai | Targeting the innate immune system to induce long-term tolerance and to resolve macrophage accumulation in atherosclerosis |
| DK3458083T5 (da) | 2016-05-18 | 2024-10-21 | Modernatx Inc | Polynukleotider, der koder for interleukin-12 (il12), og anvendelser heraf |
| JP7088911B2 (ja) | 2016-05-18 | 2022-06-21 | モデルナティエックス インコーポレイテッド | リラキシンをコードするポリヌクレオチド |
| EP4275747A3 (en) | 2016-07-19 | 2024-01-24 | Duke University | Therapeutic applications of cpf1-based genome editing |
| US12491261B2 (en) | 2016-10-26 | 2025-12-09 | Acuitas Therapeutics, Inc. | Lipid nanoparticle formulations |
| MX2019004913A (es) * | 2016-10-26 | 2019-09-16 | Curevac Ag | Vacunas de nanoparticulas lipidicas que comprenden acido ribonucleico mensajero (arnm). |
| US11583504B2 (en) | 2016-11-08 | 2023-02-21 | Modernatx, Inc. | Stabilized formulations of lipid nanoparticles |
| MA46762A (fr) * | 2016-11-10 | 2019-09-18 | Translate Bio Inc | Procédé amélioré de préparation de nanoparticules lipidiques chargées d'arnm |
| CN110167587A (zh) | 2016-11-11 | 2019-08-23 | 摩登纳特斯有限公司 | 流感疫苗 |
| BR112019014314A2 (pt) | 2017-01-11 | 2020-02-18 | The Trustees Of The University Of Pennsylvania | Composição, e, método de indução de uma resposta imune adaptativa contra vírus zika. |
| WO2018170245A1 (en) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Broad spectrum influenza virus vaccine |
| ES3020935T3 (en) | 2017-03-15 | 2025-05-23 | Modernatx Inc | Lipid nanoparticle formulation |
| CA3056133A1 (en) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Crystal forms of amino lipids |
| KR20190132405A (ko) | 2017-03-15 | 2019-11-27 | 모더나티엑스, 인크. | 치료제의 세포내 전달을 위한 화합물 및 조성물 |
| EP3600379B1 (en) * | 2017-03-31 | 2022-12-21 | Accanis Biotech F&E GmbH & Co KG | Prevention and treatment of non-melanoma skin cancer (nmsc) |
| WO2018191657A1 (en) | 2017-04-13 | 2018-10-18 | Acuitas Therapeutics, Inc. | Lipids for delivery of active agents |
| CA3061326A1 (en) | 2017-04-27 | 2018-11-01 | The Johns Hopkins University | Nucleoside-modified mrna-lipid nanoparticle lineage vaccine for hepatitis c virus |
| ES2981244T3 (es) | 2017-04-28 | 2024-10-07 | Acuitas Therapeutics Inc | Novedosas formulaciones de nanopartículas de lípidos de carbonilo y lípidos para la administración de ácidos nucleicos |
| US12077501B2 (en) | 2017-06-14 | 2024-09-03 | Modernatx, Inc. | Compounds and compositions for intracellular delivery of agents |
| US20200131498A1 (en) | 2017-06-14 | 2020-04-30 | Modernatx, Inc. | Polynucleotides encoding methylmalonyl-coa mutase |
| WO2018232357A1 (en) | 2017-06-15 | 2018-12-20 | Modernatx, Inc. | Rna formulations |
| EP3662913A4 (en) * | 2017-08-04 | 2021-06-30 | Kyowa Kirin Co., Ltd. | Nucleic-acid-containing lipid nanoparticles |
| US11639329B2 (en) | 2017-08-16 | 2023-05-02 | Acuitas Therapeutics, Inc. | Lipids for use in lipid nanoparticle formulations |
| US11542225B2 (en) | 2017-08-17 | 2023-01-03 | Acuitas Therapeutics, Inc. | Lipids for use in lipid nanoparticle formulations |
| EP4501322A3 (en) | 2017-08-17 | 2025-04-16 | Acuitas Therapeutics, Inc. | Lipids for use in lipid nanoparticle formulations |
| WO2019036030A1 (en) | 2017-08-17 | 2019-02-21 | Acuitas Therapeutics, Inc. | LIPIDS FOR USE IN LIPID NANOPARTICLE FORMULATIONS |
| WO2019046809A1 (en) | 2017-08-31 | 2019-03-07 | Modernatx, Inc. | METHODS OF MANUFACTURING LIPID NANOPARTICLES |
| WO2019053012A1 (en) | 2017-09-13 | 2019-03-21 | Biontech Rna Pharmaceuticals Gmbh | RNA REPLICON FOR THE REPROGRAMMING OF SOMATIC CELLS |
| US20200283497A1 (en) | 2017-09-13 | 2020-09-10 | Biontech Cell & Gene Therapies Gmbh | Rna replicon for expressing at cell receptor or an artificial t cell receptor |
| KR102762217B1 (ko) * | 2017-10-20 | 2025-02-07 | 비온테크 에스이 | 치료법에 적합한 리포조말 rna 제형의 제조 및 저장 |
| AU2019219200B2 (en) | 2018-02-12 | 2025-02-13 | BioNTech SE | Treatment using cytokine encoding RNA |
| CA3093509A1 (en) | 2018-03-15 | 2019-09-19 | Biontech Rna Pharmaceuticals Gmbh | 5'-cap-tri nucleotide- or higher oligonucleotide compounds and their uses in stabilizing rna, expressing proteins and in therapy |
| JP7550745B2 (ja) | 2018-07-24 | 2024-09-13 | バイオエヌテック エスエー | Ｉｌ２アゴニスト |
| WO2020020444A1 (en) | 2018-07-24 | 2020-01-30 | Biontech Rna Pharmaceuticals Gmbh | Individualized vaccines for cancer |
| WO2020037102A1 (en) * | 2018-08-15 | 2020-02-20 | University Of Florida Research Foundation, Inc. | Methods of sensitizing tumors to treatment with immune checkpoint inhibitors |
| AU2019345104B2 (en) * | 2018-09-18 | 2025-06-12 | Universiteit Gent | Therapeutic nanoparticles and methods of use thereof |
| AU2019345067A1 (en) | 2018-09-19 | 2021-04-08 | Modernatx, Inc. | High-purity peg lipids and uses thereof |
| WO2020061367A1 (en) | 2018-09-19 | 2020-03-26 | Modernatx, Inc. | Compounds and compositions for intracellular delivery of therapeutic agents |
| US12151029B2 (en) | 2018-09-19 | 2024-11-26 | Modernatx, Inc. | PEG lipids and uses thereof |
| WO2020061457A1 (en) | 2018-09-20 | 2020-03-26 | Modernatx, Inc. | Preparation of lipid nanoparticles and methods of administration thereof |
| IL281615B2 (en) | 2018-09-21 | 2026-01-01 | Acuitas Therapeutics Inc | Systems and methods for producing lipid nanoparticles and liposomes |
| US12583816B2 (en) | 2018-10-18 | 2026-03-24 | Acuitas Therapeutics, Inc. | Lipids for lipid nanoparticle delivery of active agents |
| WO2020144295A1 (en) | 2019-01-10 | 2020-07-16 | Biontech Rna Pharmaceuticals Gmbh | Localized administration of rna molecules for therapy |
| JP7523449B2 (ja) | 2019-01-11 | 2024-07-26 | アクイタス セラピューティクス インコーポレイテッド | 活性剤の脂質ナノ粒子送達のための脂質 |
| EP3911678A1 (en) | 2019-01-14 | 2021-11-24 | Genentech, Inc. | Methods of treating cancer with a pd-1 axis binding antagonist and an rna vaccine |
| AU2020217868A1 (en) | 2019-02-08 | 2021-08-12 | Biontech Cell & Gene Therapies Gmbh | Chimeric antigen receptor-modified cells for the treatment of CLDN6-expressing cancers |
| KR20210124236A (ko) | 2019-02-08 | 2021-10-14 | 비온테크 쎌 & 제네 테라피스 게엠베하 | Car-조작된 t 세포 및 사이토카인을 수반한 치료 |
| EP3917562A1 (en) | 2019-03-12 | 2021-12-08 | BioNTech SE | Therapeutic rna for prostate cancer |
| WO2020190750A1 (en) | 2019-03-15 | 2020-09-24 | Modernatx, Inc. | Hiv rna vaccines |
| AU2020242254B2 (en) | 2019-03-18 | 2026-03-12 | Biontech Cell & Gene Therapies Gmbh | Interleukin-2 receptor (il2r) and interleukin-2 (il2) variants for specific activation of immune effector cells |
| WO2020200472A1 (en) * | 2019-04-05 | 2020-10-08 | Biontech Rna Pharmaceuticals Gmbh | Preparation and storage of liposomal rna formulations suitable for therapy |
| WO2020200481A1 (en) | 2019-04-05 | 2020-10-08 | Biontech Rna Pharmaceuticals Gmbh | Treatment involving interleukin-2 (il2) and interferon (ifn) |
| WO2020242720A1 (en) | 2019-05-02 | 2020-12-03 | University Of Florida Research Foundation, Inc. | Compositions for treatment of diffuse intrinsic pontine glioma |
| WO2020234410A1 (en) * | 2019-05-20 | 2020-11-26 | Biontech Rna Pharmaceuticals Gmbh | Therapeutic rna for ovarian cancer |
| TW202115105A (zh) | 2019-06-24 | 2021-04-16 | 德商拜恩迪克Ｒｎａ製藥有限公司 | Ｉｌ２激動劑 |
| WO2021008708A1 (en) * | 2019-07-18 | 2021-01-21 | Biontech Rna Pharmaceuticals Gmbh | Method for determining at least one parameter of a sample composition comprising nucleic acid, such as rna, and optionally particles |
| MX2022003269A (es) | 2019-09-19 | 2022-07-04 | Modernatx Inc | Compuestos lipidicos de cola ramificada y composiciones para la administracion intracelular de agentes terapeuticos. |
| CA3155015A1 (en) | 2019-09-19 | 2021-03-25 | Modernatx, Inc. | Carbonate containing lipid compounds and compositions for intracellular delivery of therapeutic agents |
| US20220409708A1 (en) * | 2019-11-01 | 2022-12-29 | Korea Advanced Institute Of Science And Technology | Small lipid nanoparticles, and cancer vaccine including same |
| AU2020379482B2 (en) * | 2019-11-07 | 2026-05-07 | Samyang Holdings Corporation | Polymer nanoparticle composition for inducing immunity and preparation method therefor |
| EP3819377A1 (en) | 2019-11-08 | 2021-05-12 | Justus-Liebig-Universität Gießen | Circular rna and uses thereof for inhibiting rna-binding proteins |
| WO2021129927A1 (en) | 2019-12-23 | 2021-07-01 | Biontech Cell & Gene Therapies Gmbh | Treatment with immune effector cells engineered to express an antigen receptor |
| WO2021129945A1 (en) | 2019-12-27 | 2021-07-01 | Biontech Cell & Gene Therapies Gmbh | In vitro and in vivo gene delivery to immune effector cells using nanoparticles functionalized with designed ankyrin repeat proteins (darpins) |
| KR20220136378A (ko) | 2020-01-31 | 2022-10-07 | 제넨테크, 인크. | Pd-1 축 결합 길항제 및 rna 백신을 이용하여 네오에피토프-특이적 t 세포를 유도하는 방법 |
| WO2021155916A1 (en) | 2020-02-04 | 2021-08-12 | BioNTech SE | Treatment involving antigen vaccination and binding agents binding to pd-l1 and cd137 |
| WO2021158996A1 (en) * | 2020-02-05 | 2021-08-12 | University Of Florida Research Foundation, Incorporated | Rna-loaded nanoparticles and use thereof for the treatment of cancer |
| CA3171370A1 (en) | 2020-03-16 | 2021-09-23 | Ugur Sahin | Antigen-specific t cell receptors and t cell epitopes |
| WO2021197589A1 (en) | 2020-03-31 | 2021-10-07 | BioNTech SE | Treatment involving non-immunogenic rna for antigen vaccination |
| US12194157B2 (en) | 2020-04-09 | 2025-01-14 | Finncure Oy | Carrier for targeted delivery to a host |
| GB2613457B (en) | 2020-04-09 | 2023-12-06 | Verve Therapeutics Inc | Base editing of angptl3 and methods of using same for treatment of disease |
| AU2021252164A1 (en) | 2020-04-09 | 2022-12-15 | Finncure Oy | Mimetic nanoparticles for preventing the spreading and lowering the infection rate of novel coronaviruses |
| CN113521269A (zh) | 2020-04-22 | 2021-10-22 | 生物技术Rna制药有限公司 | 冠状病毒疫苗 |
| EP4162034A1 (en) | 2020-06-04 | 2023-04-12 | BioNTech SE | Rna replicon for versatile and efficient gene expression |
| WO2025056938A1 (en) | 2023-09-11 | 2025-03-20 | BioNTech SE | Rna compositions for delivery of incretin agents |
| CA3182579A1 (en) | 2020-07-07 | 2022-01-13 | Ugur Sahin | Therapeutic rna for hpv-positive cancer |
| JP7798855B2 (ja) | 2020-07-16 | 2026-01-14 | アクイタス セラピューティクス インコーポレイテッド | 脂質ナノ粒子に使用するためのカチオン性脂質 |
| CN115997254A (zh) | 2020-07-17 | 2023-04-21 | 基因泰克公司 | 基于注意力的神经网络用以预测肽结合、呈递和免疫原性 |
| KR20230066395A (ko) | 2020-09-08 | 2023-05-15 | 제넨테크, 인크. | 연동 펌프 및 댐프너를 사용하여 약학적 조성물을 생성하기 위한 시스템 및 방법 |
| TW202228727A (zh) * | 2020-10-01 | 2022-08-01 | 德商拜恩迪克公司 | 適用於治療之微脂體ｒｎａ調配物之製備及儲存 |
| CA3197951A1 (en) | 2020-11-11 | 2022-05-19 | Ugur Sahin | Monoclonal antibodies directed against programmed death-1 protein and their use in medicine |
| EP4008785A1 (en) | 2020-12-03 | 2022-06-08 | Justus-Liebig-Universität Gießen | Circular nucleic acids and uses thereof for interfering with genome expression and proliferation of coronaviruses |
| WO2022135667A1 (en) | 2020-12-21 | 2022-06-30 | BioNTech SE | Therapeutic rna for treating cancer |
| WO2022135666A1 (en) | 2020-12-21 | 2022-06-30 | BioNTech SE | Treatment schedule for cytokine proteins |
| TW202245808A (zh) | 2020-12-21 | 2022-12-01 | 德商拜恩迪克公司 | 用於治療癌症之治療性ｒｎａ |
| IT202100003470A1 (it) | 2021-02-16 | 2022-08-16 | Fond Toscana Life Sciences | Vaccines against sars-cov-2 |
| US11524023B2 (en) | 2021-02-19 | 2022-12-13 | Modernatx, Inc. | Lipid nanoparticle compositions and methods of formulating the same |
| CN117440834A (zh) * | 2021-03-08 | 2024-01-23 | 艾金株式会社 | 核糖核酸的体内递送用组合物及其制备方法 |
| AU2022239614A1 (en) | 2021-03-19 | 2023-10-12 | Icahn School Of Medicine At Mount Sinai | Compounds for regulating trained immunity, and their methods of use |
| CN117750974A (zh) | 2021-04-20 | 2024-03-22 | 生物技术欧洲股份公司 | 病毒疫苗 |
| US20240321387A1 (en) | 2021-05-04 | 2024-09-26 | BioNTech SE | Immunogen selection |
| IL309021A (en) | 2021-06-08 | 2024-01-01 | Biontech Cell & Gene Therapies Gmbh | Agents and methods for activation and targeting of immune effector cells |
| WO2023006920A1 (en) | 2021-07-29 | 2023-02-02 | BioNTech SE | Compositions and methods for treatment of melanoma |
| WO2023030635A1 (en) | 2021-09-02 | 2023-03-09 | BioNTech SE | Potency assay for therapeutic potential of coding nucleic acid |
| WO2023051926A1 (en) | 2021-09-30 | 2023-04-06 | BioNTech SE | Treatment involving non-immunogenic rna for antigen vaccination and pd-1 axis binding antagonists |
| WO2023061550A1 (en) | 2021-10-11 | 2023-04-20 | BioNTech SE | Therapeutic rna for lung cancer |
| TW202333803A (zh) | 2021-10-11 | 2023-09-01 | 德商拜恩迪克公司 | 用於肺癌之治療性ｒｎａ（一） |
| TW202333802A (zh) | 2021-10-11 | 2023-09-01 | 德商拜恩迪克公司 | 用於肺癌之治療性rna(二) |
| US20240366754A1 (en) | 2021-10-15 | 2024-11-07 | BioNTech SE | Pharmaceutical compositions for delivery of viral antigens and related methods |
| AU2022369342A1 (en) | 2021-10-18 | 2024-03-14 | BioNTech SE | Modified replicable rna and related compositions and their use |
| WO2023066874A1 (en) | 2021-10-18 | 2023-04-27 | BioNTech SE | Methods for determining mutations for increasing modified replicable rna function and related compositions and their use |
| CN118900696A (zh) | 2021-10-19 | 2024-11-05 | 科学医疗有限责任公司 | 雄性避孕 |
| AU2021470029A1 (en) | 2021-10-21 | 2024-05-02 | BioNTech SE | Coronavirus vaccine |
| WO2023067193A2 (en) | 2021-10-22 | 2023-04-27 | BioNTech SE | Compositions for administration of different doses of rna |
| CN118414429A (zh) | 2021-10-28 | 2024-07-30 | 生物技术欧洲股份公司 | Rna构建体及其用途 |
| FR3129833B1 (fr) | 2021-12-03 | 2024-09-06 | Univ Claude Bernard Lyon | Nanoparticules pour la liberation d’acides nucleiques |
| WO2024046572A1 (en) | 2022-09-01 | 2024-03-07 | BioNTech SE | Chimeric antigen receptor-modified cells for the treatment of cldn6 expressing cancer |
| AU2022405694A1 (en) | 2021-12-09 | 2024-07-04 | BioNTech SE | Chimeric antigen receptor-modified cells for the treatment of cldn6 expressing cancer |
| CA3242402A1 (en) | 2021-12-16 | 2023-06-22 | Acuitas Therapeutics, Inc. | Lipids for use in lipid nanoparticle formulations |
| WO2023126053A1 (en) | 2021-12-28 | 2023-07-06 | BioNTech SE | Lipid-based formulations for administration of rna |
| EP4469063A1 (en) | 2022-01-27 | 2024-12-04 | BioNTech SE | Pharmaceutical compositions for delivery of herpes simplex virus antigens and related methods |
| WO2023148276A1 (en) | 2022-02-02 | 2023-08-10 | BioNTech SE | Agents and methods for targeted delivery to cells |
| AU2023216437A1 (en) | 2022-02-02 | 2024-08-15 | BioNTech SE | Agents and methods for targeted delivery of nucleic acids to cells |
| WO2023161350A1 (en) | 2022-02-24 | 2023-08-31 | Io Biotech Aps | Nucleotide delivery of cancer therapy |
| WO2023213378A1 (en) | 2022-05-02 | 2023-11-09 | BioNTech SE | Replicon compositions and methods of using same for the treatment of diseases |
| US11932693B2 (en) | 2022-05-12 | 2024-03-19 | BioNTech SE | Monoclonal antibodies directed against programmed death-1 protein and their use in medicine |
| WO2023237726A1 (en) | 2022-06-10 | 2023-12-14 | Pantarhei Oncology B.V. | An intracellular tumor-specific variant of human zona pellucida glycoprotein 3 and nucleic acids coding therefor for use in the treatment of cancer |
| KR20250044484A (ko) | 2022-06-24 | 2025-03-31 | 튠 쎄라퓨틱스, 인코포레이티드 | 표적 유전자 억제를 통해 저밀도 지단백질을 감소시키기 위한 조성물, 시스템, 및 방법 |
| WO2024002985A1 (en) | 2022-06-26 | 2024-01-04 | BioNTech SE | Coronavirus vaccine |
| WO2024017479A1 (en) | 2022-07-21 | 2024-01-25 | BioNTech SE | Multifunctional cells transiently expressing an immune receptor and one or more cytokines, their use and methods for their production |
| CN115300641B (zh) * | 2022-08-01 | 2025-03-04 | 深圳市人民医院 | 一种靶向树突状细胞促进抗原溶酶体逃逸激活免疫系统的抗原递送载体其制备方法与应用 |
| US20260048110A1 (en) | 2022-08-03 | 2026-02-19 | BioNTech SE | Rna for preventing or treating tuberculosis |
| WO2024027910A1 (en) | 2022-08-03 | 2024-02-08 | BioNTech SE | Rna for preventing or treating tuberculosis |
| CA3267295A1 (en) | 2022-09-15 | 2024-03-21 | TRON – TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITATSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITAT MAINZ GEMEINNUTZIGE GMBH-Aysegul YILDIZ | SYSTEMS AND COMPOSITIONS CONTAINING TRANS-AMPLIFYING RNA VECTORS WITH MIARN |
| WO2024063788A1 (en) | 2022-09-23 | 2024-03-28 | BioNTech SE | Compositions for delivery of malaria antigens and related methods |
| WO2024063789A1 (en) | 2022-09-23 | 2024-03-28 | BioNTech SE | Compositions for delivery of malaria antigens and related methods |
| AU2023347390A1 (en) | 2022-09-23 | 2025-04-10 | BioNTech SE | Compositions for delivery of plasmodium csp antigens and related methods |
| CN120225219A (zh) | 2022-09-23 | 2025-06-27 | 生物技术欧洲股份公司 | 用于递送肝期抗原的组合物及相关方法 |
| IL319652A (en) | 2022-10-04 | 2025-05-01 | BioNTech SE | RNA structures and their uses |
| AU2023379446A1 (en) | 2022-11-15 | 2025-05-15 | Genentech, Inc. | Selection of diverse candidate peptides for peptide therapeutics |
| KR20250122520A (ko) | 2022-12-20 | 2025-08-13 | 제넨테크, 인크. | Pd-1 축 결합 길항제 및 rna 백신을 이용한 췌장암 치료 방법 |
| WO2024153324A1 (en) | 2023-01-18 | 2024-07-25 | BioNTech SE | Rna formulations for pharmaceutical use |
| WO2024157221A1 (en) | 2023-01-27 | 2024-08-02 | BioNTech SE | Pharmaceutical compositions for delivery of herpes simplex virus glycoprotein c, glycoprotein d, and glycoprotein e antigens and related methods |
| WO2024160826A1 (en) | 2023-01-31 | 2024-08-08 | BioNTech SE | Compositions and methods |
| WO2024165146A1 (en) | 2023-02-07 | 2024-08-15 | Biontech Cell & Gene Therapies Gmbh | Immune effector cells stably and transiently expressing nucleic acids |
| CN121002196A (zh) | 2023-02-28 | 2025-11-21 | 百欧恩泰欧洲股份公司 | 用于多种编码核酸的接头序列效力测定 |
| WO2024180363A1 (en) | 2023-02-28 | 2024-09-06 | BioNTech SE | Linker sequence potency assays for multiple coding nucleic acids |
| WO2024216217A1 (en) | 2023-04-14 | 2024-10-17 | BioNTech SE | Hiv vaccine |
| EP4694919A1 (en) | 2023-04-14 | 2026-02-18 | BioNTech SE | Rna for preventing or treating tuberculosis |
| WO2024213776A1 (en) | 2023-04-14 | 2024-10-17 | BioNTech SE | Rna for preventing or treating tuberculosis |
| CN121398842A (zh) | 2023-04-14 | 2026-01-23 | 百欧恩泰欧洲股份公司 | 用于预防或治疗结核病的rna |
| KR20260010716A (ko) | 2023-05-01 | 2026-01-21 | 예일 유니버시티 | 요법용 항원-특이적 생리학적 수지상 세포 |
| KR20260012231A (ko) | 2023-05-01 | 2026-01-26 | 예일 유니버시티 | 백신접종용 항원-특이적 생리학적 수지상 세포 |
| AU2024265158A1 (en) | 2023-05-03 | 2025-11-06 | BioNTech SE | Optimized csp variants and related methods |
| WO2024228044A1 (en) | 2023-05-03 | 2024-11-07 | BioNTech SE | Optimized csp variants and related methods |
| TW202449804A (zh) | 2023-05-15 | 2024-12-16 | 美商建南德克公司 | 用於定相腫瘤中的突變之系統及方法 |
| CN119997938A (zh) * | 2023-06-05 | 2025-05-13 | 安徽医科大学第一附属医院 | 肺靶向纳米胶束、制备方法及应用 |
| WO2025024324A1 (en) | 2023-07-21 | 2025-01-30 | BioNTech SE | Compositions for delivery of plasmodium antigens and related methods |
| IL325865A (en) | 2023-07-21 | 2026-03-01 | BioNTech SE | Compositions for administering Plasmodium antigens and related methods |
| WO2025021277A1 (en) * | 2023-07-21 | 2025-01-30 | BioNTech SE | Agents and methods for targeted delivery of cytokines to immune cells |
| WO2025024337A1 (en) | 2023-07-24 | 2025-01-30 | BioNTech SE | Compositions for delivery of plasmodium antigens and related methods |
| CN121772938A (zh) | 2023-08-03 | 2026-03-31 | 百欧恩泰欧洲股份公司 | 用于递送单纯疱疹病毒抗原的药物组合物及相关方法 |
| WO2025030154A1 (en) | 2023-08-03 | 2025-02-06 | The Trustees Of The University Of Pennsylvania | Pharmaceutical compositions for delivery of herpes simplex virus glycoprotein b antigens and related methods |
| WO2025040709A1 (en) | 2023-08-24 | 2025-02-27 | BioNTech SE | Systems and compositions comprising highly active trans-amplifying replicases |
| WO2025054556A1 (en) | 2023-09-07 | 2025-03-13 | BioNTech SE | Rna compositions for delivery of mpox antigens and related methods |
| WO2025051381A1 (en) | 2023-09-08 | 2025-03-13 | BioNTech SE | Methods and compositions for localized expression of administered rna |
| AU2024343011A1 (en) | 2023-09-11 | 2026-03-26 | BioNTech SE | Rna compositions for delivery of incretin agents |
| WO2025061863A1 (en) | 2023-09-20 | 2025-03-27 | BioNTech SE | Method |
| WO2025083147A1 (en) | 2023-10-17 | 2025-04-24 | Transimmune Ag | Methods for analyzing immune responses and antigen profiling |
| TW202539697A (zh) | 2023-11-15 | 2025-10-16 | 德商拜恩技術股份公司 | 冠狀病毒疫苗 |
| WO2025117816A1 (en) * | 2023-12-01 | 2025-06-05 | Recode Therapeutics, Inc. | Lipid nanoparticle compositions and uses thereof |
| WO2025144938A1 (en) | 2023-12-26 | 2025-07-03 | Emmune, Inc. | Systems for nucleic acid transfer |
| WO2025149492A1 (en) | 2024-01-08 | 2025-07-17 | BioNTech SE | Rna encoding an immune inhibitory il-1 family member |
| WO2025155607A1 (en) | 2024-01-16 | 2025-07-24 | Genentech, Inc. | Methods of treating urothelial carcinoma with a pd-1 axis binding antagonist and an rna vaccine |
| IT202400004828A1 (it) | 2024-03-05 | 2025-09-05 | Fond Toscana Life Sciences | Proteine spike mutate come vaccini contro sars-cov-2 |
| WO2025202937A1 (en) | 2024-03-26 | 2025-10-02 | BioNTech SE | Cancer vaccines |
| WO2025201659A1 (en) | 2024-03-28 | 2025-10-02 | BioNTech SE | Combination therapy comprising therapeutic rna cancer vaccines and anti-ctla4 antibodies for cancer treatment |
| WO2025209797A1 (en) | 2024-04-03 | 2025-10-09 | BioNTech SE | Interleukin 18 receptor agents for specific activation of immune effector cells |
| WO2025213131A1 (en) | 2024-04-05 | 2025-10-09 | BioNTech SE | Rna compositions for delivery of orthopox antigens and related methods |
| CN118001254B (zh) | 2024-04-09 | 2024-07-26 | 北京悦康科创医药科技股份有限公司 | 靶向抗原呈递细胞的脂质组合物及其应用 |
| WO2025223684A1 (en) | 2024-04-23 | 2025-10-30 | BioNTech SE | Methods and compositions for stimulating immune response |
| WO2025224684A1 (en) | 2024-04-24 | 2025-10-30 | BioNTech SE | Compositions and methods for producing engineered immune cells |
| WO2025264662A1 (en) | 2024-06-18 | 2025-12-26 | BioNTech SE | Compositions and methods for treatment of melanoma |
| WO2026015882A1 (en) | 2024-07-12 | 2026-01-15 | BioNTech SE | Hsv antigen fragments and related methods |
| WO2026041793A1 (en) | 2024-08-23 | 2026-02-26 | BioNTech SE | Chimeric proteins comprising non-human protein domains for enhancing antigenicity |
| WO2026047153A1 (en) | 2024-08-28 | 2026-03-05 | BioNTech SE | Potency assay for multiple coding nucleic acids |
| WO2026047148A1 (en) | 2024-08-29 | 2026-03-05 | BioNTech SE | Minimal polypeptide-encoding rnas |
| WO2026074196A1 (en) | 2024-10-05 | 2026-04-09 | Yale University | Checkpoint inhibitor loaded activated dendritic cells |
| WO2026074195A1 (en) | 2024-10-05 | 2026-04-09 | Yale University | Cytokine loaded activated dendritic cells |
Family Cites Families (118)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4897355A (en) | 1985-01-07 | 1990-01-30 | Syntex (U.S.A.) Inc. | N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
| US5804381A (en) | 1996-10-03 | 1998-09-08 | Cornell Research Foundation | Isolated nucleic acid molecule encoding an esophageal cancer associated antigen, the antigen itself, and uses thereof |
| US5703055A (en) * | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| US5264618A (en) | 1990-04-19 | 1993-11-23 | Vical, Inc. | Cationic lipids for intracellular delivery of biologically active molecules |
| US6235525B1 (en) | 1991-05-23 | 2001-05-22 | Ludwig Institute For Cancer Research | Isolated nucleic acid molecules coding for tumor rejection antigen precursor MAGE-3 and uses thereof |
| EP0826063A1 (en) | 1995-04-25 | 1998-03-04 | Vical Incorporated | Single-vial formulations of dna/lipid complexes |
| US7422902B1 (en) | 1995-06-07 | 2008-09-09 | The University Of British Columbia | Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer |
| JPH11510046A (ja) | 1995-07-21 | 1999-09-07 | ローヌ−プーラン ローラー ファーマシューティカルズ インコーポレイテッド | アデノ関連ウイルスリポソーム及び樹状細胞をトランスフェクトして特異性免疫を刺激することにおけるそれらの使用 |
| JP4108126B2 (ja) | 1996-04-26 | 2008-06-25 | リュクスウニヴェルシテート テ レイデン | Ｔ細胞ペプチド・エピトープの選択と産生方法および選択したエピトープを組込むワクチン |
| ATE395904T1 (de) | 1996-09-13 | 2008-06-15 | Lipoxen Technologies Ltd | Liposome |
| EP0839912A1 (en) | 1996-10-30 | 1998-05-06 | Instituut Voor Dierhouderij En Diergezondheid (Id-Dlo) | Infectious clones of RNA viruses and vaccines and diagnostic assays derived thereof |
| US6074645A (en) | 1996-11-12 | 2000-06-13 | City Of Hope | Immuno-reactive peptide CTL epitopes of human cytomegalovirus |
| KR20010024585A (ko) | 1997-11-06 | 2001-03-26 | 로셰 디아그노스틱스 게엠베하 | 종양-특이적 항원, 이들의 제조방법, 및 이들의 면역화 및진단에서의 용도 |
| US6432925B1 (en) | 1998-04-16 | 2002-08-13 | John Wayne Cancer Institute | RNA cancer vaccine and methods for its use |
| AU6289699A (en) | 1998-10-05 | 2000-04-26 | Genzyme Corporation | Genes differentially expressed in cancer cells to design cancer vaccines |
| WO2000067761A1 (en) | 1999-05-06 | 2000-11-16 | Wake Forest University | Compositions and methods for identifying antigens which elicit an immune response |
| JP5640237B2 (ja) | 1999-11-30 | 2014-12-17 | ルードヴィッヒ インスティテュート フォー キャンサー リサーチ リミテッド | 癌関連抗原をコードする単離された核酸分子、その抗原そのものおよびその使用 |
| US7462354B2 (en) | 1999-12-28 | 2008-12-09 | Pharmexa Inc. | Method and system for optimizing minigenes and peptides encoded thereby |
| EP1242108B1 (en) | 1999-12-28 | 2007-07-11 | Pharmexa Inc. | Optimized minigenes and peptides encoded thereby |
| EP1292331A2 (en) | 2000-06-07 | 2003-03-19 | Biosynexus Incorporated | Immunostimulatory rna/dna hybrid molecules |
| US6472176B2 (en) | 2000-12-14 | 2002-10-29 | Genvec, Inc. | Polynucleotide encoding chimeric protein and related vector, cell, and method of expression thereof |
| EP1903054A3 (de) | 2001-06-05 | 2008-07-23 | CureVac GmbH | Stabilisierte mRNA mit erhöhtem G/C-Gehalt und optimierter Codon Usage für die Gentherapie |
| DE10162480A1 (de) | 2001-12-19 | 2003-08-07 | Ingmar Hoerr | Die Applikation von mRNA für den Einsatz als Therapeutikum gegen Tumorerkrankungen |
| AUPS054702A0 (en) | 2002-02-14 | 2002-03-07 | Immunaid Pty Ltd | Cancer therapy |
| WO2003106692A2 (en) | 2002-06-13 | 2003-12-24 | Merck Patent Gmbh | Methods for the identification of all-antigens and their use for cancer therapy and transplantation |
| DE10229872A1 (de) | 2002-07-03 | 2004-01-29 | Curevac Gmbh | Immunstimulation durch chemisch modifizierte RNA |
| DK1592441T3 (da) * | 2003-02-06 | 2012-05-14 | Aduro Biotech | Listeria, hvis indtrængen i ikke-phagocytiske celler er svækket, vacciner omfattende listeria og fremgangsmåder til anvendelse deraf |
| DE10344799A1 (de) | 2003-09-26 | 2005-04-14 | Ganymed Pharmaceuticals Ag | Identifizierung von Oberflächen-assoziierten Antigenen für die Tumordiagnose und -therapie |
| DE10347710B4 (de) * | 2003-10-14 | 2006-03-30 | Johannes-Gutenberg-Universität Mainz | Rekombinante Impfstoffe und deren Verwendung |
| EP2286794B8 (en) | 2003-10-15 | 2016-06-01 | SynCore Biotechnology CO., LTD | Use of cationic liposomes comprising paclitaxel |
| DE602004030369D1 (de) | 2003-10-24 | 2011-01-13 | Immunaid Pty Ltd | Therapieverfahren |
| US7303881B2 (en) | 2004-04-30 | 2007-12-04 | Pds Biotechnology Corporation | Antigen delivery compositions and methods of use |
| DE102004023187A1 (de) | 2004-05-11 | 2005-12-01 | Ganymed Pharmaceuticals Ag | Identifizierung von Oberflächen-assoziierten Antigenen für die Tumordiagnose und -therapie |
| DE102004057303A1 (de) | 2004-11-26 | 2006-06-01 | Merck Patent Gmbh | Stabile Kristallmodifikationen von DOTAP Chlorid |
| SG158155A1 (en) | 2004-12-29 | 2010-01-29 | Mannkind Corp | Methods to bypass cd+4 cells in the induction of an immune response |
| PL2161336T5 (pl) | 2005-05-09 | 2017-10-31 | Ono Pharmaceutical Co | Ludzkie przeciwciała monoklonalne przeciwko białku Programmed Death 1 (PD-1) oraz sposoby leczenia raka z zastosowaniem samych przeciwciał anty-PD-1 lub w połączeniu z innymi środkami immunoterapeutycznymi |
| CA2612241C (en) | 2005-07-01 | 2018-11-06 | Medarex, Inc. | Human monoclonal antibodies to programmed death ligand 1 (pd-l1) |
| HUE043492T2 (hu) | 2005-08-23 | 2019-08-28 | Univ Pennsylvania | Módosított nukleozidokat tartalmazó RNS és eljárások az alkalmazására |
| DE102005041616B4 (de) | 2005-09-01 | 2011-03-17 | Johannes-Gutenberg-Universität Mainz | Melanom-assoziierte MHC Klasse I assoziierte Oligopeptide und für diese kodierende Polynukleotide und deren Verwendungen |
| EP1762575A1 (en) | 2005-09-12 | 2007-03-14 | Ganymed Pharmaceuticals AG | Identification of tumor-associated antigens for diagnosis and therapy |
| GB0519303D0 (en) * | 2005-09-21 | 2005-11-02 | Oxford Biomedica Ltd | Chemo-immunotherapy method |
| US20090186042A1 (en) | 2006-02-27 | 2009-07-23 | Arizona Board Of Regents For And On Behalf Of Arizona State University | Identification and use of novopeptides for the treatment of cancer |
| US20090304711A1 (en) | 2006-09-20 | 2009-12-10 | Drew Pardoll | Combinatorial Therapy of Cancer and Infectious Diseases with Anti-B7-H1 Antibodies |
| DE102006060824B4 (de) | 2006-12-21 | 2011-06-01 | Johannes-Gutenberg-Universität Mainz | Nachweis von individuellen T-Zell-Reaktionsmustern gegen Tumor-assoziierte Antigene (TAA) in Tumorpatienten als Basis für die individuelle therapeutische Vakzinierung von Patienten |
| CA2947292C (en) | 2006-12-27 | 2019-07-23 | Emory University | Compositions and methods for the treatment of infections and tumors |
| DE102007001370A1 (de) * | 2007-01-09 | 2008-07-10 | Curevac Gmbh | RNA-kodierte Antikörper |
| CA2675378A1 (en) | 2007-01-29 | 2008-08-07 | Medipol Sa | Chitosan-based colloidal particles for rna delivery |
| EP1955695A1 (en) * | 2007-02-06 | 2008-08-13 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Nanocapsules of lipophilic complexes of nucleic acids |
| US8140270B2 (en) | 2007-03-22 | 2012-03-20 | National Center For Genome Resources | Methods and systems for medical sequencing analysis |
| US8877206B2 (en) | 2007-03-22 | 2014-11-04 | Pds Biotechnology Corporation | Stimulation of an immune response by cationic lipids |
| US20090004213A1 (en) | 2007-03-26 | 2009-01-01 | Immatics Biotechnologies Gmbh | Combination therapy using active immunotherapy |
| KR101586617B1 (ko) | 2007-06-18 | 2016-01-20 | 머크 샤프 앤 도메 비.브이. | 사람 프로그램된 사멸 수용체 ｐｄ-1에 대한 항체 |
| EP2060583A1 (en) | 2007-10-23 | 2009-05-20 | Ganymed Pharmaceuticals AG | Identification of tumor-associated markers for diagnosis and therapy |
| US9274119B2 (en) * | 2008-01-11 | 2016-03-01 | The University Of Tokyo | Anti-CLDN6 antibody |
| UA105764C2 (uk) | 2008-03-24 | 2014-06-25 | 4 Сц Аг | Заміщені імідазохіноліни |
| AU2009236306B2 (en) | 2008-04-17 | 2015-04-02 | Pds Biotechnology Corporation | Stimulation of an immune response by enantiomers of cationic lipids |
| PL215513B1 (pl) * | 2008-06-06 | 2013-12-31 | Univ Warszawski | Nowe boranofosforanowe analogi dinukleotydów, ich zastosowanie, czasteczka RNA, sposób otrzymywania RNA oraz sposób otrzymywania peptydów lub bialka |
| US20110111044A1 (en) | 2008-07-31 | 2011-05-12 | Enzon Pharmaceuticals, Inc. | Nanoparticle compositions for nucleic acids delivery system |
| JP5382682B2 (ja) | 2008-09-01 | 2014-01-08 | 国立大学法人 長崎大学 | 薬物送達複合体 |
| WO2010037408A1 (en) * | 2008-09-30 | 2010-04-08 | Curevac Gmbh | Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof |
| JP5777519B2 (ja) * | 2008-10-09 | 2015-09-09 | テクミラ ファーマシューティカルズ コーポレイション | 改良されたアミノ脂質および核酸の送達方法 |
| DE102008061522A1 (de) | 2008-12-10 | 2010-06-17 | Biontech Ag | Verwendung von Flt3-Ligand zur Verstärkung von Immunreaktionen bei RNA-Immunisierung |
| EP2451475A2 (en) * | 2009-07-06 | 2012-05-16 | Novartis AG | Self replicating rna molecules and uses thereof |
| EP3165234B1 (de) | 2009-07-31 | 2019-04-03 | ethris GmbH | Rna mit einer kombination aus unmodifizierten und modifizierten nucleotiden zur proteinexpression |
| WO2011071860A2 (en) * | 2009-12-07 | 2011-06-16 | Alnylam Pharmaceuticals, Inc. | Compositions for nucleic acid delivery |
| WO2013040142A2 (en) | 2011-09-16 | 2013-03-21 | Iogenetics, Llc | Bioinformatic processes for determination of peptide binding |
| WO2011127255A1 (en) | 2010-04-08 | 2011-10-13 | Merck Sharp & Dohme Corp. | Preparation of lipid nanoparticles |
| KR102095670B1 (ko) | 2010-05-14 | 2020-03-31 | 더 제너럴 하스피톨 코포레이션 | 종양 특이적 신생항원을 확인하는 조성물 및 방법 |
| AU2011276234B2 (en) * | 2010-07-06 | 2016-02-25 | Glaxosmithkline Biologicals S.A. | Liposomes with lipids having an advantageous pKa- value for RNA delivery |
| BR112013004879A2 (pt) * | 2010-08-31 | 2018-04-24 | Novartis Ag | lipossomas pequenos para entrega de rna que codifica imunogénio |
| ES3005233T3 (en) | 2010-10-01 | 2025-03-14 | Modernatx Inc | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof |
| CN102133404B (zh) | 2011-03-23 | 2013-01-16 | 成都诺恩生物科技有限公司 | 一种肿瘤靶向治疗药物载体、其制备方法及其应用 |
| JP2014511687A (ja) | 2011-03-31 | 2014-05-19 | モデルナ セラピューティクス インコーポレイテッド | 工学操作された核酸の送達および製剤 |
| DE102011102734A1 (de) | 2011-05-20 | 2012-11-22 | WMF Württembergische Metallwarenfabrik Aktiengesellschaft | Vorrichtung zum Aufschäumen von Milch, Getränkebereiter mit dieser Vorrichtung und Verfahren zum Aufschäumen von Milch |
| EP4014966A1 (en) * | 2011-07-06 | 2022-06-22 | GlaxoSmithKline Biologicals S.A. | Liposomes having useful n:p ratio for delivery of rna molecules |
| AU2012280901B2 (en) * | 2011-07-06 | 2016-11-10 | Glaxosmithkline Biologicals S.A. | Oil-in-water emulsions that contain nucleic acids |
| EP2763701B1 (en) | 2011-10-03 | 2018-12-19 | Moderna Therapeutics, Inc. | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof |
| JP2015501844A (ja) | 2011-12-16 | 2015-01-19 | モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． | 修飾ヌクレオシド、ヌクレオチドおよび核酸組成物 |
| WO2013106496A1 (en) | 2012-01-10 | 2013-07-18 | modeRNA Therapeutics | Methods and compositions for targeting agents into and across the blood-brain barrier |
| WO2013113325A1 (en) | 2012-01-31 | 2013-08-08 | Curevac Gmbh | Negatively charged nucleic acid comprising complexes for immunostimulation |
| WO2013124701A2 (en) | 2012-02-20 | 2013-08-29 | Universita' Degli Studi Di Milano | New homo- and heterodimeric smac mimetic compounds as apoptosis inducers |
| WO2013143555A1 (en) * | 2012-03-26 | 2013-10-03 | Biontech Ag | Rna formulation for immunotherapy |
| RS58794B1 (sr) | 2012-03-26 | 2019-07-31 | Biontech Rna Pharmaceuticals Gmbh | Formulacija rnk za imunoterapiju |
| US20130255281A1 (en) | 2012-03-29 | 2013-10-03 | General Electric Company | System and method for cooling electrical components |
| WO2013151663A1 (en) | 2012-04-02 | 2013-10-10 | modeRNA Therapeutics | Modified polynucleotides for the production of membrane proteins |
| ES2729759T3 (es) | 2012-07-12 | 2019-11-06 | Persimmune Inc | Vacunas contra el cáncer personalizadas y terapias celulares inmunitarias adoptivas |
| EP2914728B1 (en) | 2012-11-01 | 2020-07-08 | Factor Bioscience Inc. | Methods and products for expressing proteins in cells |
| ES2921623T3 (es) | 2012-11-26 | 2022-08-30 | Modernatx Inc | ARN modificado terminalmente |
| EP2931319B1 (en) | 2012-12-13 | 2019-08-21 | ModernaTX, Inc. | Modified nucleic acid molecules and uses thereof |
| US20160022840A1 (en) | 2013-03-09 | 2016-01-28 | Moderna Therapeutics, Inc. | Heterologous untranslated regions for mrna |
| US20160024181A1 (en) | 2013-03-13 | 2016-01-28 | Moderna Therapeutics, Inc. | Long-lived polynucleotide molecules |
| US20160032316A1 (en) | 2013-03-14 | 2016-02-04 | The Trustees Of The University Of Pennsylvania | Purification and Purity Assessment of RNA Molecules Synthesized with Modified Nucleosides |
| US10258698B2 (en) | 2013-03-14 | 2019-04-16 | Modernatx, Inc. | Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions |
| EP2971161B1 (en) | 2013-03-15 | 2018-12-26 | ModernaTX, Inc. | Ribonucleic acid purification |
| WO2014144711A1 (en) | 2013-03-15 | 2014-09-18 | Moderna Therapeutics, Inc. | Analysis of mrna heterogeneity and stability |
| EP2983804A4 (en) | 2013-03-15 | 2017-03-01 | Moderna Therapeutics, Inc. | Ion exchange purification of mrna |
| WO2014144039A1 (en) | 2013-03-15 | 2014-09-18 | Moderna Therapeutics, Inc. | Characterization of mrna molecules |
| EP2971033B8 (en) | 2013-03-15 | 2019-07-10 | ModernaTX, Inc. | Manufacturing methods for production of rna transcripts |
| US10077439B2 (en) | 2013-03-15 | 2018-09-18 | Modernatx, Inc. | Removal of DNA fragments in mRNA production process |
| BR112015025460B1 (pt) | 2013-04-07 | 2024-01-02 | The Broad Institute, Inc. | Método para a produção de uma vacina personalizada contra a neoplasia para um indivíduo diagnosticado como tendo uma neoplasia, vacina personalizada e uso da mesma |
| WO2015014375A1 (en) | 2013-07-30 | 2015-02-05 | Biontech Ag | Tumor antigens for determining cancer therapy |
| US20160194625A1 (en) | 2013-09-03 | 2016-07-07 | Moderna Therapeutics, Inc. | Chimeric polynucleotides |
| WO2015034925A1 (en) | 2013-09-03 | 2015-03-12 | Moderna Therapeutics, Inc. | Circular polynucleotides |
| US9925277B2 (en) | 2013-09-13 | 2018-03-27 | Modernatx, Inc. | Polynucleotide compositions containing amino acids |
| AU2013401479B2 (en) | 2013-09-26 | 2019-04-04 | BioNTech SE | Particles comprising a shell with RNA |
| WO2015051169A2 (en) | 2013-10-02 | 2015-04-09 | Moderna Therapeutics, Inc. | Polynucleotide molecules and uses thereof |
| WO2015051173A2 (en) | 2013-10-02 | 2015-04-09 | Moderna Therapeutics, Inc | Polynucleotide molecules and uses thereof |
| WO2015058780A1 (en) | 2013-10-25 | 2015-04-30 | Biontech Ag | Method and kit for determining whether a subject shows an immune response |
| WO2015085318A2 (en) | 2013-12-06 | 2015-06-11 | Moderna Therapeutics, Inc. | Targeted adaptive vaccines |
| US20150167017A1 (en) | 2013-12-13 | 2015-06-18 | Moderna Therapeutics, Inc. | Alternative nucleic acid molecules and uses thereof |
| CA2938700A1 (en) | 2014-02-05 | 2015-08-13 | Biontech Ag | A cannula, an injection or infusion device and methods of using the cannula or the injection or infusion device |
| DK3134131T3 (en) | 2014-04-23 | 2022-02-07 | Modernatx Inc | Nucleic acid vaccines |
| WO2015172843A1 (en) | 2014-05-16 | 2015-11-19 | Biontech Diagnostics Gmbh | Methods and kits for the diagnosis of cancer |
| WO2016062323A1 (en) | 2014-10-20 | 2016-04-28 | Biontech Ag | Methods and compositions for diagnosis and treatment of cancer |
| ES2946969T3 (es) | 2014-12-12 | 2023-07-28 | CureVac SE | Moléculas de ácido nucleico artificiales para una expresión proteica mejorada |
| JP6907116B2 (ja) | 2014-12-30 | 2021-07-21 | キュアバック アーゲー | 人工核酸分子 |
| WO2016155809A1 (en) | 2015-03-31 | 2016-10-06 | Biontech Rna Pharmaceuticals Gmbh | Lipid particle formulations for delivery of rna and water-soluble therapeutically effective compounds to a target cell |
| KR102762217B1 (ko) * | 2017-10-20 | 2025-02-07 | 비온테크 에스이 | 치료법에 적합한 리포조말 rna 제형의 제조 및 저장 |
-
2012
- 2012-03-26 WO PCT/EP2012/001319 patent/WO2013143555A1/en not_active Ceased
-
2013
- 2013-03-25 TR TR2019/04758T patent/TR201904758T4/tr unknown
- 2013-03-25 ES ES13713356T patent/ES2719480T3/es active Active
- 2013-03-25 HU HUE13713356 patent/HUE044594T2/hu unknown
- 2013-03-25 WO PCT/EP2013/000902 patent/WO2013143683A1/en not_active Ceased
- 2013-03-25 CA CA3088428A patent/CA3088428C/en active Active
- 2013-03-25 LT LTEP13713356.7T patent/LT2830593T/lt unknown
- 2013-03-25 PT PT13713356T patent/PT2830593T/pt unknown
- 2013-03-25 PL PL20189077.9T patent/PL3777840T3/pl unknown
- 2013-03-25 DK DK13713356.7T patent/DK2830593T3/da active
- 2013-03-25 BR BR112014022562A patent/BR112014022562A8/pt not_active Application Discontinuation
- 2013-03-25 CN CN201380016262.0A patent/CN104302276A/zh active Pending
- 2013-03-25 MX MX2014011466A patent/MX377244B/es active IP Right Grant
- 2013-03-25 JP JP2015502136A patent/JP6279545B2/ja active Active
- 2013-03-25 RS RS20201186A patent/RS61002B1/sr unknown
- 2013-03-25 LT LTEP18171522.8T patent/LT3427723T/lt unknown
- 2013-03-25 ES ES18171522T patent/ES2823239T3/es active Active
- 2013-03-25 SM SM20200603T patent/SMT202000603T1/it unknown
- 2013-03-25 US US14/388,192 patent/US10485884B2/en active Active
- 2013-03-25 HU HUE18171522A patent/HUE052485T2/hu unknown
- 2013-03-25 SI SI201331795T patent/SI3427723T1/sl unknown
- 2013-03-25 AU AU2013242512A patent/AU2013242512B2/en active Active
- 2013-03-25 NZ NZ628328A patent/NZ628328A/en unknown
- 2013-03-25 DK DK20189077.9T patent/DK3777840T3/da active
- 2013-03-25 CA CA2864253A patent/CA2864253C/en active Active
- 2013-03-25 PT PT181715228T patent/PT3427723T/pt unknown
- 2013-03-25 CN CN201811246680.XA patent/CN109331176B/zh active Active
- 2013-03-25 ES ES20189077T patent/ES3030907T3/es active Active
-
2014
- 2014-09-24 MX MX2020011781A patent/MX2020011781A/es unknown
- 2014-09-24 MX MX2020011696A patent/MX2020011696A/es unknown
-
2017
- 2017-11-14 JP JP2017219079A patent/JP6596478B2/ja active Active
- 2017-12-18 AU AU2017279565A patent/AU2017279565B2/en active Active
-
2018
- 2018-11-28 JP JP2018222175A patent/JP6832904B2/ja active Active
-
2019
- 2019-09-23 US US16/578,601 patent/US11559587B2/en active Active
-
2020
- 2020-03-26 AU AU2020202152A patent/AU2020202152B2/en active Active
- 2020-04-06 JP JP2020068394A patent/JP7096282B2/ja active Active
- 2020-10-05 HR HRP20201578TT patent/HRP20201578T1/hr unknown
-
2022
- 2022-11-30 US US18/071,705 patent/US20230226217A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NL301079I2 (nl) | isatuximab | |
| HUE052485T2 (hu) | RNA készítmény immunterápiára | |
| DK3311834T3 (da) | Formulering til anti-alfa4beta7-antistof | |
| DK3623481T3 (da) | Sammensætninger til nukleinsyresekventering | |
| SI3725778T1 (sl) | Formulacije enzalutamida | |
| DK2858671T3 (da) | Antistofformulering | |
| DK2890397T3 (da) | Antiprolactinreceptor-antistofformulering | |
| DK2768524T3 (da) | PD-L1-baseret immunterapi | |
| DK3117837T3 (da) | Antistofformuleringer | |
| EP2892404A4 (en) | WAFFLE | |
| HUE037048T2 (hu) | Eljárások 4-cikloalkiloxibenzolszulfonamidok elõállítására | |
| BR112014032798A2 (pt) | composição | |
| DK2877019T3 (da) | Sikkerede herbisidiske sammensætninger til anvendelse i ris | |
| DK2800476T3 (da) | Fremgangsmåde til fodring | |
| BR112014000015A2 (pt) | formulação | |
| DK2849760T3 (da) | Fremgangsmåder til oligonukleotid-chelatkompleks | |
| DK2868318T4 (da) | Injicerbar formulering | |
| DK2788353T3 (da) | Bur-aminligander til metallo-radiofarmaceutika | |
| DK3415158T3 (da) | Repeat-variable direster til targeting af nukleotider | |
| EP2770828A4 (en) | FORMULATION | |
| FR2992364B1 (fr) | Turbopompe | |
| BR112014032712A2 (pt) | composição | |
| DK2809343T3 (da) | Fremgangsmåde til fermentering | |
| FR2991392B1 (fr) | Turbopompe | |
| DK3427723T3 (da) | Rna-formulering til immunterapi |